A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PRIORITI
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 30 May 2016 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.